TRAW (Traws Pharma, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by TRAW officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-16 | Charles David Pauza | Chief Science Officer Virology | A | — | — |
| 2026-07-15 | WERNER CAUTREELS | Director | A | — | — |
| 2026-07-15 | Nikolay Savchuk | Chief Operating Officer | A | — | — |
| 2026-07-14 | Charles Nolan Parker | Chief Financial Officer | A | — | — |
| 2026-07-14 | Robert Redfield | Chief Medical Officer | A | — | — |
| 2026-07-14 | Mary Teresa Shoemaker | Director | A | — | — |
| 2026-07-14 | John Harold Leaman | Director | A | — | — |
| 2026-07-14 | Iain D. Dukes | Chief Executive Officer | A | — | — |
| 2026-07-14 | JACK E STOVER | Director | A | — | — |
| 2026-07-14 | Trafford Clarke | Director | A | — | — |
| 2026-04-28 | OrbiMed Capital GP VIII LLC | 10%+ Owner | Buy | — | — |
| 2026-04-08 | Charles Nolan Parker | Chief Financial Officer | A | — | — |
| 2026-03-10 | JACK E STOVER | Director | A | — | — |
| 2026-03-10 | Iain D. Dukes | Chief Executive Officer | A | — | — |
| 2026-03-10 | WERNER CAUTREELS | Director | A | — | — |
| 2026-03-10 | Nikolay Savchuk | Chief Operating Officer | A | — | — |
| 2026-03-10 | Trafford Clarke | Director | A | — | — |
| 2026-03-10 | Robert Redfield | Chief Medical Officer | A | — | — |
| 2026-03-10 | Mary Teresa Shoemaker | Director | A | — | — |
| 2026-03-10 | John Harold Leaman | Director | A | — | — |
| 2026-03-10 | Charles David Pauza | Chief Science Officer Virology | A | — | — |
| 2025-12-16 | Nikolay Savchuk | Chief Operating Officer | A | — | — |
| 2025-12-16 | Charles David Pauza | Chief Science Officer Virology | A | — | — |
| 2025-12-16 | Robert Redfield | Chief Medical Officer | A | — | — |
| 2025-12-16 | JACK E STOVER | Director | A | — | — |
| 2025-12-16 | Trafford Clarke | Director | A | — | — |
| 2025-12-16 | WERNER CAUTREELS | Director | A | — | — |
| 2025-12-16 | Iain D. Dukes | Chief Executive Officer | A | — | — |
| 2025-12-16 | Mary Teresa Shoemaker | Director | A | — | — |
| 2025-12-16 | John Harold Leaman | Director | A | — | — |
| 2025-11-25 | John Harold Leaman | Director | A | — | — |
| 2025-10-15 | WERNER CAUTREELS | Director | A | — | — |
| 2025-10-15 | JACK E STOVER | Director | A | — | — |
| 2025-10-15 | Nikolay Savchuk | Chief Operating Officer | A | — | — |
| 2025-10-15 | Charles David Pauza | Chief Science Officer Virology | A | — | — |
| 2025-10-15 | Mary Teresa Shoemaker | Director | A | — | — |
| 2025-10-15 | Iain D. Dukes | Chief Executive Officer | A | — | — |
| 2025-10-15 | Robert Redfield | Chief Medical Officer | A | — | — |
| 2025-10-15 | Trafford Clarke | Director | A | — | — |
| 2025-10-14 | John Harold Leaman | Director | A | — | — |
| 2025-06-23 | Mary Teresa Shoemaker | Director | A | — | — |
| 2025-06-23 | WERNER CAUTREELS | Director | A | — | — |
| 2025-06-23 | Trafford Clarke | Director | A | — | — |
| 2025-06-23 | JACK E STOVER | Director | A | — | — |
| 2025-04-08 | TPAV, LLC | 10%+ Owner | J | — | — |
| 2025-02-19 | WERNER CAUTREELS | Chief Executive Officer | M | — | — |
| 2025-01-27 | OrbiMed Capital GP VIII LLC | 10%+ Owner | Buy | — | — |
| 2025-01-27 | Nikolay Savchuk | Chief Operating Officer | Buy | — | — |
| 2025-01-27 | TPAV, LLC | 10%+ Owner | Buy | — | — |
| 2025-01-27 | WERNER CAUTREELS | Chief Executive Officer | Buy | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 1,203,250 | — |
| — | Chief Executive Officer | 236,934 | — |
| — | Chief Operating Officer | 216,410 | — |
| — | Chief Science Officer Virology | 115,971 | — |
| — | Chief Medical Officer | 113,919 | — |
| — | Director | 109,222 | — |
| — | Chief Financial Officer | 15,393 | — |
| — | Director | 6,292 | — |
| — | Director | 6,165 | — |
| — | Director | 6,157 | — |
| — | Director | 4,058 | — |
| — | CFO | 1,570 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TRAW quote page; the site-wide leaderboard is on the insider transactions hub.